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Introduction
Mesenchymal stem cells (MSCs) were originally des-
cribed by Friedenstein and colleagues [1,2] in the non-
hematopoietic component of bone marrow where they 
participate in regulating hematopoietic stem cell matura-
tion and emigration into the circulation. Since that time, 
they have been isolated from the connective tissue of 
almost all organs, including adipose, periosteum, synovial 
ﬂ   uid, muscle, hair follicles, root of deciduous teeth, 
articular cartilage, placenta, dermis, umbilical cord, 
Wharton’s jelly, lung, liver and spleen [3-5]. It has been 
posited that MSCs in these organs, like other stem cells, 
function as a source of cells for replacement and 
regeneration during normal cellular turnover, repair of 
injured tissue, or in response to biological aging.
MSCs were identiﬁ  ed based on their ability to undergo 
diﬀ   erentiation into mesenchymal lineage cell types, 
including bone, cartilage, adipose tissue, muscle and 
tendon [4]. Th  e diﬀ   erentiation capacity of MSCs was 
initially thought to be limited to their tissue of origin; 
however, studies have demonstrated that MSCs have the 
capacity to diﬀ   erentiate into cells of mesodermal, 
endodermal and ectodermal origins, at least in vitro
[4,6-8]. Th   e therapeutic application of MSCs was 
suggested from early observations in preclinical animal 
models of disease, in which transplanted MSCs homed to 
sites of inﬂ  ammation within damaged tissues where some 
of the transplanted cells underwent diﬀ  erentiation  to 
replace injured cells. However, it quickly became evident 
in a variety of disease models that the levels of improve-
ment mediated by MSCs do not always correlate with the 
levels of cellular engraftment and diﬀ  erentiation  ob-
served. As such, diﬀ  erentiation may not be a primary 
mechanism by which MSCs mediate tissue repair. Rather, 
it has been widely reported that MSCs secrete bioactive 
levels of soluble factors (growth factors and cytokines) 
capable of paracrine regulation of diverse disease-asso-
ciated processes, including activation of tissue-resident 
stem/progenitor cells, apoptosis, stimulation of vasculo-
genesis and inhibition of inﬂ  ammation [9-15]. A rapidly 
growing body of literature indicates that MSCs possess 
immunosuppressive properties [16-23]. Th  erefore, the 
reparative function of MSCs observed in so many injury 
models may be, at least in part, attributed to the produc-
tion of paracrine factors that direct inhibition of immune 
responses and function. It is also apparent that MSCs 
secrete pro-inﬂ   ammatory cytokines that may enhance 
innate immunity. Increasing evidence suggests that 
activation of Toll-like receptors (TLRs), one of the early 
immune sensors, modulates this distinct MSC activity 
[24-29]. Th  e underlying factors produced by MSCs and 
their immunomodulatory mechanisms are reviewed 
here. Additionally, a newly described mechanism of 
polarization in which MSCs can be induced to be either 
pro- or anti-inﬂ   ammatory through diﬀ  erential  TLR 
activation is presented.
Immununomodulation by mesenchymal stem cells
Anti-infl  ammatory and immune suppressive mediators
Th  e immune suppression activities of MSCs were ﬁ  rst 
described in ex vivo allogeneic co-cultures of leukocytes 
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(BMSCs) [16,30-32]. Th   ese early observations instigated 
numerous studies exploring the immunomodulatory 
eﬀ  ect of MSCs derived from a variety of sources and 
species. BMSCs express low levels of human leukocyte 
antigen (HLA) major histocompatibility complex (MHC) 
class I, do not express co-stimulatory molecules (B7-1 
and -2, CD40, or CD40L), and can be induced to express 
MHC class II and Fas ligand. Th  ese features are often 
used to explain their ‘immune privileged’ status in 
allogeneic hosts. Furthermore, BMSCs inhibit dendritic 
cell maturation, B and T cell proliferation and diﬀ  eren-
tiation, attenuate natural killer cell activity, as well as 
support the production of suppressive T regulatory cells 
(Tregs) [16,33-36]. While the mechanisms underlying the 
immune modulating property of BMSCs are not fully 
understood, they are dependent on the secretion of 
soluble factors as well as direct BMSC-to-immune cell 
contact [33]. To date, at least 14 factors produced by 
BMSCs have been associated with their anti-inﬂ  am  ma-
tory properties. Some soluble factors are produced by 
BMSCs constitutively while others are induced by BMSC 
interaction with inﬂ   ammatory cells and factors com-
monly present in sites of tissue injury.
Th  e expression of indoleamine 2,3-dioxygenase (IDO) 
and inducible nitric-oxide synthase (iNOS) by BMSCs 
has been associated with repression of T-cell proliferation 
[37-39]. Recently, secretion of IDO by BMSCs was shown 
in vivo to both inhibit the proliferation of acetylcholine 
receptor-speciﬁ  c T cells and B cells and to normalize the 
distribution of Th  1,  Th  2,  Th   17 and Treg cells in experi-
mental autoimmune myasthenia gravis that is character-
ized by alteration in the balance of these four Th    subsets 
[40]. IDO catalyzes the conversion of tryptophan, an 
essential amino acid for T-cell proliferation, into 
kynurenine. IDO has been shown to exert its immuno-
suppressive eﬀ   ect through the local accumulation of 
tryptophan metabolites, rather than through tryptophan 
depletion [41]. Expression of IDO by BMSCs was thought 
to be IFN-γ dependent [37,41-44]. However, Opitz and 
colleagues [45] recently demonstrated that IDO expres-
sion in BMSCs can also be upregulated by activation of 
TLR3 and TLR4 via induction of an autocrine IFN-β 
signaling loop involving protein kinase R and indepen-
dent of IFN-γ. Interestingly, when human BMSCs were 
treated with IFN-γ in vitro, they expressed extremely 
high levels of IDO and very low levels of iNOS, whereas 
mouse BMSCs expressed abundant iNOS and very little 
IDO. Th   ese data suggest there is species variation in the 
mechanisms of BMSC immunosuppression [46].
Prostaglandin E2 (PGE-2) is emerging as a central 
mediator of many of the anti-inﬂ  ammatory properties of 
BMSCs [5,35]. PGE-2 is synthesized from arachidonic 
acid by cyclooxygenase (COX) enzymes COX-1 and 
COX-2. COX-1 is constitutively expressed in BMSCs and 
COX-2 expression can be induced by inﬂ  ammatory cyto-
kines such as IL-1β, IL-6, IFN-γ and TNF-α [47]. Inhibi-
tors of PGE-2 synthesis have been shown to abrogate 
BMSC anti-proliferative eﬀ   ects on T [16,48,49] and 
natural killer cells [48,50] and almost completely abrogate 
the immunosuppressive eﬀ  ects of BMSCs in vitro [47]. 
PGE-2 also plays a major role in the BMSC-mediated 
inhibition of dendritic cell maturation [51-53]. Nemeth 
and colleagues [34] showed in an animal model of sepsis 
that BMSCs (activated by lipopolysaccharide (LPS) or 
TNF-α) release PGE-2 that acts on the EP2 and EP4 
receptors of macrophages leading to the production and 
release of IL-10, a potent anti-inﬂ  ammatory  cyto  kine, 
and decreased production of the pro-inﬂ  ammatory cyto-
kines TNF-α and IL-6. Th  e reprogramming of macro-
phages into a regulatory-like proﬁ   le was also demon-
strated in vitro by Maggini and colleagues [54].
Transforming growth factor (TGF)-β1, a well-charac-
terized anti-inﬂ   ammatory cytokine, is constitutively 
expressed by BMSCs [31]. Neutralizing antibodies to 
TGF-β1 have been reported to impair the immuno  modu-
latory function of BMSCs on T [31] and natural killer 
cells [50]. However, others have reported that TGF-β1 
has no eﬀ  ect on the immunosuppressive properties of 
BMSCs [32,55]. Th   ese discrepancies may be explained by 
the experimental conditions used in these studies. Th  e 
importance of TGF-β1 in vivo was recently demonstrated 
in a mouse model of ragweed-induced asthma [56]. 
Inject  ing BMSCs into ragweed-sensitized mice signiﬁ  -
cantly improved lung pathology upon allergen challenge. 
Th   e presence of pre-exisiting TGF-β-speciﬁ  c neutralizing 
antibodies eliminated the beneﬁ  cial eﬀ  ects of the BMSCs; 
furthermore, injection of BMSCs derived from TGF-β1 
knockout mice had no beneﬁ  cial eﬀ  ect, suggesting that 
the BMSC-derived TGF-β1 is critical in suppressing the 
allergic responses. Treatment with BMSCs also increased 
the total number of Tregs in this model. Although 
Nemeth and colleagues did not directly connect BMSC-
derived TGF-β1 to the recruitment of Tregs, Patel and 
colleagues [57] demonstrated that in co-cultures of 
peripheral blood mononuclear cells and BMSCs, TGF-β1 
produced by BMSCs resulted in increased numbers of 
Tregs.
Other factors associated with the immune modulating 
properties of BMSCs include HLA-G (reviewed in [58]), 
hepatocyte growth factor (HGF) [31,59], leukemia 
inhibitory factor (LIF) [60,61], IL1 receptor antagonist 
(IL1RA) [62,63], CCL-2 [64], galectin-3, galectin-1 and 
semaphorin-3A [65,66]. All of these soluble factors are 
capable of inhibiting T-cell proliferation, are highly 
expressed by BMSCs and thus may contribute to their 
immunosuppressive properties [65,66]. More recently, a 
new role was advanced for TNF-α-induced protein 6 
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and colleagues [67] found that  intravenously infused 
human BMSCs embolized in the lung and expressed high 
levels of TSG-6. TSG-6 secretion is known to suppress 
inﬂ  am  mation through the inhibition of the inﬂ  ammatory 
network of proteases primarily by increasing the inhibi-
tory activity of inter-α-inhibitor, sequestration of hya-
luro  nan fragments and decreasing neutrophil inﬁ  ltra  tion 
into sites of inﬂ  ammation [68-71]. In a model of acute 
inﬂ   ammation induced by myocardial infarction,  the 
knockdown of TSG-6 expression by small interfering 
RNA in human BMSCs signiﬁ   cantly reduced MSC-
mediated improvements of inﬂ  ammatory  responses. 
Further  more, the administration of recombinant TSG-6 
protein largely duplicated the therapeutic eﬀ  ects of the 
delivered BMSCs on inﬂ  ammatory responses and infarct 
size [67]. Together these results suggest that TSG-6 may 
play a key role in the anti-inﬂ  ammatory eﬀ  ects of BMSCs.
Pro-infl  ammatory mediators
Th   ough we are beginning to better understand the many 
complex mechanisms associated with the secretion by 
BMSCs of immune suppressive mediators like TSG-6, so 
far only a few reports have described the contrasting pro-
inﬂ  ammatory activity of BMSCs. Indeed, the observation 
of this divergent immune eﬀ  ect by the BMSCs came from 
studies primarily focused on the downstream conse-
quences of TLR stimulation within these cells. TLRs are a 
conserved family of receptors that recognize pathogen-
associated molecular patterns (PAMPs) and promote the 
activation of immune cells [72-76]. Many TLRs (TLR1 to 
TLR13) have been identiﬁ   ed and characterized in a 
variety of immune cell types and species. Agonists for 
TLRs include exogenous microbial components, such as 
LPS (TLR2 and 4), lipoproteins and peptidoglycans 
(TLR1, 2, 6), viral RNA (TLR3), bacterial and viral un-
methylated CpG-DNA (TLR9), and endogenous mole-
cules shed following cell injury, including heat shock 
proteins and extracellular matrix molecules [72-77]. 
Speciﬁ   c agonist engagement of TLRs leads to the 
expression of inﬂ  ammatory cytokines or co-stimulatory 
molecules by a MyD88 (a TLR adapter protein)-depen-
dent or MyD88-independent signaling pathways and can 
promote chemotaxis of the stimulated cell. TLRs are 
diﬀ  erentially expressed on leukocyte subsets and non-
immune cells and may regulate important aspects of 
innate and adaptive immune responses [24,27,75,78,79].
MSCs are among the cells that express an array of 
TLRs, including TLR2, 3, 4, 5, 6 and 9 [24,27,28]. Further-
more, studies by our group established that the 
stimulation of MSCs with TLR agonists leads to the 
activa  tion of downstream signaling pathways, including 
NF-kB, AKT and mitogen-activated protein kinase 
(MAPK). Consequently, activation of these pathways 
triggers the previously unreported induction and secre-
tion of pro-inﬂ   ammatory cytokines, chemokines and 
related TLR gene products. Interestingly, the unique 
patterns of aﬀ   ected genes, cytokines and chemokines 
measured identiﬁ  ed the TLRs as potential players in the 
established MSC immunomodulatory properties as well 
as their ability to migrate towards injured tissues. 
Surprisingly, we noted that TLR4 stimulation with LPS 
led to the secretion of primarily pro-inﬂ  ammatory 
media  tors, such as IL-1β, IL-6, IL-8, IL-12, type I IFNs 
and TNF-α [28]. Th   ough unexpected, previous observa-
tions reported by Beyth and colleagues [80] recognized 
that LPS priming aﬀ  ected co-cultures of leukocytes with 
human MSCs and attenuated the expected human MSC-
mediated inhibition of T-lymphocyte activation as well as 
aﬀ   ected their capacity to secrete interferon. More 
recently, Romieu-Mourez and colleagues [81] showed 
that TLR stimulation in murine MSCs similarly resulted 
in the production of inﬂ  ammatory mediators, such as 
IL-1, IL-6, IL-8, and CCL5. Furthermore, they demon-
strated that TLR and IFN activated murine MSCs 
injected within Matrigel matrices into mice resulted in 
the formation of an inﬂ  ammatory site attracting innate 
immune cells and resulting in a dramatic recruitment of 
neutrophils. Raicevic and colleagues [82], studying the 
eﬀ  ect of TLR activation within MSCs in an inﬂ  ammatory 
milieu, observed that this environment shifted the 
cytokine proﬁ  le to a pro-inﬂ  ammatory one rather than 
the expected immunosuppressive one. Th  ey similarly 
observed an increase in IL-1β, IL-6, and IL-12 after TLR 
activation in this inﬂ  ammatory context.
Th  e eﬀ  ects of TLR engagement on the typical MSC 
properties of tri-lineage diﬀ  erentiation  (chondrogenic, 
osteogenic, adipogenic) and proliferation have also been 
assessed. For instance, Hwa Cho and colleagues  [27] 
described a role for TLRs in proliferation and diﬀ  erentia-
tion of human adipose-derived mesenchymal stem cells 
(ASCs) [24]. In another report, murine BMSCs were 
found to express TLRs that, upon activation, aﬀ  ected 
their proliferation and diﬀ   erentiation. In contrast to 
human BMSCs, they suggested that activation of TLR2 
inhibits both diﬀ   erentiation and migration of murine 
BMSCs, while also promoting their proliferation. Liotta 
and colleagues [25]  found that TLR activation had no 
eﬀ  ect on adipogenic, osteogenic, or chondrogenic diﬀ  er-
en  tiation in human BMSCs. Furthermore, this report 
suggested equivalent roles for TLR3 and TLR4 engage-
ment in human MSC-mediated immune modulation in 
contrast to those reports mentioned above. Additionally, 
Lombardo and colleagues [26] reported that TLR3 and 
TLR4 engagement within ASCs increased osteogenic 
diﬀ  erentiation but had no eﬀ  ect on adipogenic diﬀ  eren-
tiation potential or proliferation. Again diﬀ  erent from the 
observations presented by Liotta and colleagues, it was 
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does not aﬀ  ect the ability of human ASCs to suppress 
lymphocyte activation.
Th  ough somewhat confounding, this recent body of 
work on the downstream consequences of TLRs provides 
emerging evidence for a new pro-inﬂ  ammatory immune 
modulating role for BMSCs. Th  e identiﬁ   cation of the 
molecular details for this new pro-inﬂ  ammatory BMSC 
role, and whether it is innate or just an in vitro artifact, 
awaits further investigation. However, this novel obser-
vation is important to consider given the accelerated use 
of BMSCs in anti-inﬂ   ammatory cell-based therapies. 
Additionally, as Raicevic and colleagues [82] suggest, 
targeting of TLRs in BMSCs may avoid deleterious 
consequences in their use as anti-inﬂ  ammatory therapies. 
By contrast, TLR-activated pro-inﬂ  ammatory  BMSCs 
could prove useful in breaking tolerance in the therapy of 
immune evasive diseases, such as cancer.
New MSC paradigm: polarization into a pro-
infl  ammatory (MSC1) or an immunosuppressive 
(MSC2) phenotype
TLRs are vital in coordinating not only the pro-homeo-
static tissue injury responses of immune cells but also 
that of MSCs of various origins. Th   e immune modulating 
activities of MSCs downstream of TLR stimulation seem 
to be more complex than originally anticipated. In an 
attempt to resolve the conﬂ   icting data between the 
immune modulating eﬀ  ect of TLR3 and TLR4 activation 
in human MSCs, our group has proposed a new MSC 
Table 1. The eff  ects of toll-like receptor stimulation on mesenchymal stem cells
       Eff  ect of TLR stimulation and references
Stem cell property  TLR2 (Pam3Cys)  TLR3 (Poly(I:C))  TLR4 (LPS+)  TLR5 (Flagellin)  TLR9 (CpG-ODNs)
Proliferation      
  hADSCs  NC [24,26]  NC [24,26]  NC [24,26]     [24]
  hMSCs    NC [28,45]  NC [86],  [87,88]   
 muMSCs   [27]     [27]   
Migration      
 hMSCs     [28,29]   [28,29]   [28]   [28]
 muMSCs    [27]     
Diff   erentiation      
  Cartilage      
  hMSCs    NC  [25]  NC  [25]   
  muMSCs    [27]     
  Bone      
  hADSCs   [24], NC [26]   [26], NC [24]   [24,26]  NC [24]   [24]
  hMSCs       [29], NC [25]   
  muMSCs    [27]     
       
  Adipose      
    hADSCs  NC [24,26]  NC [24,26]  NC [24,26]  NC [24]  NC [24,26]
  hMSCs     [29]   [29]   
  muMSCs    [27]     
Immune  suppression      
  hADSCs  NC [26]  NC [26]  NC [26]   
 hMSCs     [28,29,45]   [45]   
  muMSCs  NC  [27]     
Immune  stimulation      
  hADSCs  NC  [24,26]     
 hMSCs     [25]   [25,28,29,45]   
Down arrows indicate inhibited eff  ect; up arrows indicate enhanced eff  ect; NC indicates no change or eff  ect. hADSC, human adipose-derived stem cell; hMSC, human 
mesenchymal stem cell; LPS, lipopolysaccharide; muMSC, murine mesenchymal stem cell; ODN, oligodeoxynucleotide; poly(I:C), polyinosinic:polycytidylic acid; TLR, 
toll-like receptor.
Bunnell et al. Stem Cell Research & Therapy 2010, 1:34
http://stemcellres.com/content/1/5/34
Page 4 of 8paradigm that takes its cue from the monocyte literature 
(Table 1). It is based on the premise that these hetero-
geneous cells can be induced to polarize into two diverse 
but homo  ge  neously acting phenotypes (Figure 1) [83].
It is established that stimulation of monocytes with 
known cytokines or agonists to their TLRs, including 
IFN-γ and endotoxin (LPS, TLR4-agonist), polarizes 
them into a classical M1 phenotype that participates in 
early pro-inﬂ   ammatory responses. IL-4 treatment of 
monocytes yields the alternative M2 phenotype that is 
associated with anti-inﬂ  ammatory resolution responses 
[83]. Our group proposed that human BMSCs, like 
monocytes, are polarized by downstream TLR signaling 
into two homogenously acting phenotypes, classiﬁ  ed as 
MSC1 and MSC2, following the monocyte nomenclature. 
Th  e short-term, low-level exposure or ‘priming’ we 
described with TLR4 agonists polarized human BMSCs 
toward a pro-inﬂ  ammatory MSC1 phenotype while the 
downstream consequences of TLR3 priming of human 
BMSCs polarized them toward an immunosuppressive 
(MSC2) phenotype. Th  is novel MSC polarization para-
digm is based on the consistent but novel outcomes 
observed for MSC1 when compared with MSC2 for 
several parameters, including dissimilar patterns of 
secretion of cytokines and chemokines and diﬀ  erences in 
diﬀ  erentiation capabilities, extracellular matrix deposi-
tion, TGF-β signaling pathways, and Jagged, IDO and 
PGE-2 expression [29]. Th  e most compelling outcome 
was opposite eﬀ  ects of each cell type on T-lymphocyte 
activation [29]. Recently, our group has also observed 
that the infusion of MSC1 and MSC2 cells into murine 
models of inﬂ  ammatory lung injury had disparate out-
comes. Th  e MSC1  cells aggravated the inﬂ  ammatory 
injury, while the MSC2 cells were anti-imﬂ  ammatory 
(unpublished observations).
We suggest that an immunosuppressive phenotype has 
been detected for most current BMSC preparations 
because of the manner in which the cells are isolated 
from the host and the way they are expanded in ex vivo 
culture. Furthermore, we propose that the default BMSC 
phenotype must be immunosuppressive to avoid pro  found 
and deleterious consequences of a pro-inﬂ  ammatory 
MSC1 phenotype on the hematopoietic stem cells that 
BMSCs maintain and support. While circulating or 
quiescent stem/progenitor cells are both equipped to 
respond to environmental cues, they must not actively 
engage immune cells or mediate repair while circulating 
throughout the body or maintaining hematopoietic stem 
cells in the bone marrow niche. In a manner analogous to 
the immature state maintained for monocytes, dendritic 
cells, and other immune cells, BMSCs are immune 
suppressive until a pro-inﬂ  ammatory role is required to 
promote tissue repair. More than likely, TLR4-priming is 
not the optimal way to induce the MSC1 phenotype. It is 
expected that a combination of other factors, such as 
IFNs, or direct contact with other pro-inﬂ  ammatory cells 
and their microenvironments along the lines of that 
reported by Romieu-Mourez and colleagues [81] and 
Raicevic and colleagues [82] will more readily induce the 
MSC1 phenotype. It also remains to be seen whether 
these newly described phenotypes are found in nature. 
Nonetheless, we believe that a greater understanding of 
the complexities driving the immune modulating proper-
ties of pro-inﬂ  ammatory MSC1 and immunosuppressive 
MSC2 phenotypes will allow for more successful and 
eﬀ  ective targeted MSC-based therapies.
Conclusions
Current evidence supports the utilization of MSCs for 
the treatment of the inﬂ   ammatory component of 
numerous diseases and autoimmune disorders. It is 
evident that the mechanisms by which MSCs enhance 
tissue repair are more complex than originally believed. 
MSCs secrete a wide variety of pro- and anti-inﬂ  am-
matory factors that have the potential to aﬀ  ect multiple 
processes, such as apoptosis, angiogenesis and inﬂ  am-
mation. Our group has deﬁ  ned a mechanism by which 
MSCs can undergo molecular signaling to be either anti-
inﬂ  ammatory, as widely described, or pro-inﬂ  ammatory 
based on the diﬀ  erential engagement of TLRs. As the 
application of MSC-based therapy moves forward to the 
Figure 1. Short-term and low-level priming of TLR4 (left side) 
and TLR3 (right side) leads to the polarization of heterogeneous 
BMSC preparations into a pro-infl  ammatory MSC1 phenotype 
or an immunosuppressive MSC2 phenotype [29]. The proposed 
agonists for the toll-like receptor (TLR) priming schemes are listed in 
the yellow boxes above the specifi  c priming scheme. We speculate 
that MSC1 may contribute to early tissue injury responses while MSC2 
may contribute to later tissue resolution responses based on similar 
contributions by polarized monocytes in wound healing [83-85]. 
Poly(I:C), polyinosinic:polycytidylic acid. Figure adapted from [85].
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the molecular mechanisms governing both the pro- and 
anti-inﬂ  ammatory properties of MSCs so that we can 
enhance their therapeutic eﬃ   cacy.
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